Trump Administration Makes Historic Move on Marijuana Reclassification - Here's What Changes

In a groundbreaking development that could reshape America's approach to cannabis, the Trump administration has officially reclassified FDA-approved and state-licensed medical marijuana as a less dangerous drug, moving it from the highly restrictive Schedule I category to the more lenient Schedule III classification.

Acting Attorney General Todd Blanche signed the historic order on Thursday, implementing a directive that President Trump had issued in a December executive order. This move represents a significant shift in federal drug policy, though it stops short of full federal legalization.

What This Reclassification Actually Means

While this decision won't legalize marijuana for medical or recreational use under federal law, it does align federal policy more closely with the dozens of states that have already legalized medical marijuana. The reclassification places cannabis alongside other Schedule III substances like anabolic steroids, ketamine, and products containing less than 90 milligrams of codeine.

According to the Drug Enforcement Administration, Schedule III drugs are characterized as having a "moderate to low potential for physical and psychological dependence." This is a dramatic departure from Schedule I, which is reserved for substances deemed to have no accepted medical use and high potential for abuse - a category that previously included marijuana alongside heroin, LSD, and ecstasy.

The Path to This Historic Decision

The journey to reclassification began under the Biden administration in 2022, when the former president directed the Department of Health and Human Services to study whether marijuana's Schedule I status was appropriate. The FDA's 2023 study recommended moving cannabis to Schedule III, recognizing that dozens of states had already legalized marijuana for medical use to treat conditions like chronic pain.

However, the effort stalled under Biden. It wasn't until Trump took office and signed his December executive order that momentum returned. In that order, Trump cited the 2023 FDA study and instructed then-Attorney General Pam Bondi to reschedule the drug in the "most expeditious manner."

What Changes and What Doesn't

Despite this historic shift, marijuana remains federally illegal. Interstate marijuana commerce is still prohibited, though penalties for violating federal marijuana laws may be less severe due to the drug's new Schedule III status. Currently, marijuana is legal for medicinal purposes in 40 states, with 25 states having legalized adult recreational use.

Blanche emphasized that the reclassification will facilitate "research on the safety and efficacy of this substance," potentially providing "patients with better care and doctors with more reliable information." Additionally, Blanche has scheduled a hearing for June where the Drug Enforcement Administration will consider broader reclassification of marijuana as Schedule III.

Economic Implications for Cannabis Companies

One of the most significant impacts of this reclassification could be financial. Currently, because marijuana is a Schedule I drug, cannabis companies face an effective tax rate of approximately 60% of gross revenue before business deductions. The reclassification to Schedule III is expected to substantially reduce this tax burden, potentially transforming the economics of the legal cannabis industry.

Analyst Jaret Seiberg from TD Cowen has suggested that the "most likely outcome is the status quo with states as the primary regulator of medical and recreational cannabis," though he notes these markets would "still be in violation of federal law and still at risk of a crackdown if a President at some point decides to act."

Looking Ahead

This reclassification represents a pragmatic approach to a complex issue that has seen evolving public opinion and state-level policy changes over the past decade. While it doesn't resolve the fundamental tension between state and federal law regarding marijuana, it does represent the most significant federal policy shift on cannabis in generations.

The June DEA hearing will be crucial in determining whether this reclassification extends beyond state-licensed medical marijuana to broader cannabis policy. For now, the Trump administration has taken a measured step that acknowledges the medical value of cannabis while maintaining federal oversight and control.

As this policy continues to evolve, businesses, patients, and advocates will be watching closely to see how this reclassification plays out in practice and whether it signals further changes to come in America's approach to cannabis policy.